Centre François Baclesse

Futó vizsgálatok

• Még nem toboroz

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Forrás

• Még nem toboroz

  Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

  NCT07733817· Forrás

• Toboroz

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· 1/2. fázis· Forrás

• Még nem toboroz

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· Forrás

• Még nem toboroz

  Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

  NCT07637851· 1/2. fázis· Forrás

• Még nem toboroz

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· 2/3. fázis· Forrás

• Toboroz

  A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

  NCT07451002· Forrás

• Toboroz

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· 3. fázis· Forrás

• Toboroz

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· 3. fázis· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· 3. fázis· Forrás

• Toboroz

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Forrás

• Toboroz

  Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

  NCT07205731· 2. fázis· Forrás

• Toboroz

  First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

  NCT06840782· 3. fázis· Forrás

• Még nem toboroz

  BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

  NCT07071844· 2. fázis· Forrás

• Toboroz

  A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

  NCT06868485· 2. fázis· Forrás

• Toboroz

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· 2. fázis· Forrás

• Toboroz

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· 3. fázis· Forrás

• Toboroz

  Digital Solutions for bEtter cAre

  NCT07416513· Forrás

• Toboroz

  Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

  NCT06817161· 3. fázis· Forrás

• Toboroz

  Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

  NCT06876532· Forrás

• Még nem toboroz

  Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

  NCT06681038· 2. fázis· Forrás

• Toboroz

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· 2. fázis· Forrás

• Toboroz

  Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

  NCT06603506· Forrás

• Toboroz

  Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.

  NCT06479070· Forrás

• Fut, nem toboroz

  Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

  NCT06430866· 3. fázis· Forrás

• Toboroz

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· 3. fázis· Forrás

• Toboroz

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· 2. fázis· Forrás

• Toboroz

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· 3. fázis· Forrás

• Toboroz

  FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

  NCT06393816· 2. fázis· Forrás

• Toboroz

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· 2. fázis· Forrás

• Toboroz

  CARE1 Pragmatic Clinical Trial

  NCT06364631· 3. fázis· Forrás

• Toboroz

  Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

  NCT05500391· 2. fázis· Forrás

• Toboroz

  HRD Tests for Ovarian cancER

  NCT06152731· 2. fázis· Forrás

• Toboroz

  Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

  NCT06027632· Forrás

• Toboroz

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· 3. fázis· Forrás

• Toboroz

  Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

  NCT06033183· Forrás

• Toboroz

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Forrás

• Fut, nem toboroz

  Prevention of Alopecia in Patients With Localised Breast Cancer

  NCT06011525· Forrás

• Toboroz

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· 3. fázis· Forrás

• Toboroz

  Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment

  NCT05404321· Forrás

• Toboroz

  Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

  NCT05378204· Forrás

• Toboroz

  Circulating Immunes Cells, Cytokines and Brain Radiotherapy

  NCT05082961· Forrás

• Toboroz

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· 3. fázis· Forrás

• Toboroz

  Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  NCT04747054· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

  NCT04931342· 2. fázis· Forrás

• Toboroz

  Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

  NCT05122806· Forrás

• Toboroz

  A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  NCT04913285· 1. fázis· Forrás

• Toboroz

  Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy

  NCT04767048· 2. fázis· Forrás

• Fut, nem toboroz

  Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

  NCT04940325· 2. fázis· Forrás

• Fut, nem toboroz

  Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

  NCT03915678· 2. fázis· Forrás

Showing 50 of 72.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák9 toboroz
• Petefészekrák8 toboroz
• Fej-nyaki daganatok7 toboroz
• Gyermekkori daganatok6 toboroz
• Neuroendokrin daganatok5 toboroz
• Vastagbélrák5 toboroz
• Áttétes emlőrák3 toboroz
• Gyomor- és nyelőcsőrák2 toboroz
• Hasnyálmirigyrák2 toboroz
• Hólyagrák2 toboroz
• Máj- és epeúti rák2 toboroz
• Méhtestrák2 toboroz
• Prosztatarák2 toboroz
• Szarkóma2 toboroz
• Vesedaganat2 toboroz
• Méhnyakrák1 toboroz
• Melanóma1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

  NCT06735781· Forrás

• Lezárult

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· Forrás

• Leállították

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· Forrás

• Lezárult

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· Forrás

• Leállították

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· 2. fázis· Forrás

• Lezárult

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· 2. fázis· Forrás

• Lezárult

  Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

  NCT05303129· Forrás

• Lezárult

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· 3. fázis· Forrás

• Lezárult

  Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC

  NCT04725396· Forrás

• Leállították

  Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

  NCT04450836· 2. fázis· Forrás

• Lezárult

  Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy

  NCT04481893· Forrás

• Lezárult

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· 3. fázis· Forrás

• Leállították

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· 3. fázis· Forrás

• Lezárult

  COL Immunotherapy Before Radiochimio + Ipilimumab

  NCT04256213· Forrás

• Lezárult

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· 3. fázis· Forrás

• Lezárult

  Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

  NCT03948724· Forrás

• Lezárult

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· 2. fázis· Forrás

• Lezárult

  Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

  NCT04132960· 2. fázis· Forrás

• Leállították

  Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

  NCT03673332· 4. fázis· Forrás

• Leállították

  Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  NCT03869190· 1/2. fázis· Forrás

• Lezárult

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· 2. fázis· Forrás

• Lezárult

  Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults

  NCT03670927· Forrás

• Lezárult

  Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response

  NCT03831230· Forrás

• Lezárult

  UTOLA: UTerin OLAparib

  NCT03745950· 2. fázis· Forrás

• Lezárult

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· 3. fázis· Forrás

• Lezárult

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· 3. fázis· Forrás

• Lezárult

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· Forrás

• Lezárult

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· 3. fázis· Forrás

• Lezárult

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· 3. fázis· Forrás

• Lezárult

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· 3. fázis· Forrás

• Lezárult

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· 2. fázis· Forrás

• Lezárult

  PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

  NCT03275506· 2. fázis· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· 3. fázis· Forrás

• Lezárult

  Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

  NCT03075423· 2. fázis· Forrás

• Lezárult

  A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

  NCT03194893· 3. fázis· Forrás

• Lezárult

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· 3. fázis· Forrás

• Lezárult

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· 3. fázis· Forrás

• Lezárult

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· 3. fázis· Forrás

• Lezárult

  Robotic Low Rectum Anterior Resection

  NCT04015804· Forrás

• Lezárult

  Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

  NCT02266420· Forrás

• Lezárult

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· 2. fázis· Forrás

• Lezárult

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· 3. fázis· Forrás

• Leállították

  A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer

  NCT01495676· Forrás